Effect of Zilucoplan on Myasthenia Gravis–Specific Outcome Subdomain Scores in RAISE: A Phase 3 Study (S34.004)
To evaluate the effect of zilucoplan, a macrocyclic peptide complement component 5 inhibitor, on Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) subdomain scores (ocular, bulbar, respiratory and limb/axial muscle groups) in patients with generalized myasthenia gravis (gMG).
Authors
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Miriam Freimer (ORCID: https://orcid.org/0000-0001-8282-764X)
- Channa Hewamadduma
- Angela Genge (ORCID: https://orcid.org/0000-0001-5587-9946)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Constantine Farmakidis (ORCID: https://orcid.org/0000-0002-4668-9224)
- Angelina Maniaol
- Tuan H. Vu (ORCID: https://orcid.org/0000-0001-6839-9765)
- Fiona Grimson
- Michael D. Weiss (ORCID: https://orcid.org/0000-0003-4064-1032)
- Babak Boroojerdi
- Maria Isabel Leite (ORCID: https://orcid.org/0000-0003-4407-5066)
- Nataša Savić
- Yessar Hussain
Institutions
- University of North Carolina at Chapel Hill (US)
- Oslo University Hospital (NO)
- Montreal Neurological Institute and Hospital (CA)
- University of South Florida (US)
- University of Washington Medical Center (US)
- The Ohio State University Wexner Medical Center (US)
- University of Oxford (GB)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- University of Kansas Medical Center (US)
- National Hospital Organization Hanamaki Hospital (JP)
- UCB Pharma (Germany) (DE)
- The University of Texas at Austin (US)
- University of Sheffield (GB)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208755
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00